Avalo Therapeutics (AVTX) Cash & Equivalents (2014 - 2026)
Avalo Therapeutics (AVTX) reported Cash & Equivalents of $147000.0 for Q1 2026, down 99.88% on a YoY basis from $125.0 million in Q1 2025, and up 297.3% quarter-over-quarter from $37000.0 in Q4 2025.
Avalo Therapeutics (AVTX) Cash & Equivalents (2014 - 2026) Analysis & Trends
Avalo Therapeutics has reported Cash & Equivalents for 13 years, with the latest figure at $147000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents fell 99.88% year-over-year to $147000.0; the trailing twelve-month figure through Mar 2026 stood at $147000.0 (down 99.88% YoY), and the FY2025 full-year result was $37000.0, down 99.97% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $147000.0, up from $37000.0 in the prior quarter.
- The five-year high for Cash & Equivalents was $134.5 million in Q4 2024, with the low at $1000.0 in Q3 2023.
- Historically, Cash & Equivalents has averaged $34.1 million across 5 years, with a median of $100000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 99.99% — and 2024, when it surged 13454500.0%.
- Avalo Therapeutics' Cash & Equivalents stood at $15000.0 in 2022, then plunged by 93.33% to $1000.0 in 2023, then surged by 13454500.0% to $134.5 million in 2024, then sank by 99.97% to $37000.0 in 2025, then jumped by 297.3% to $147000.0 in 2026.
- The last three Cash & Equivalents figures came in at $147000.0 (Q1 2026), $37000.0 (Q4 2025), and $90000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 558.94 Mn |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | 147,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147,000.00 |
| Dec 31, 2025 | 37,000.00 |
| Sep 30, 2025 | 90,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 125.05 Mn |
| Dec 31, 2024 | 134.55 Mn |
| Sep 30, 2024 | 81.86 Mn |
| Jun 30, 2024 | 93.43 Mn |
| Mar 31, 2024 | 110.18 Mn |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Mar 31, 2023 | 16.69 Mn |
| Dec 31, 2022 | 15,000.00 |
| Sep 30, 2022 | 16.94 Mn |
| Jun 30, 2022 | 14,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | 54.59 Mn |
| Sep 30, 2021 | 71.51 Mn |
| Jun 30, 2021 | 40.44 Mn |